SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C132 - Developing the Treatments of Tomorrow I: Taking Molecules from Lab to Man

Event Time: Tuesday April 25, 2017 1:00 pm to 3:00 pm
Topic(s): Research Methodology, Education, and History
Director(s): Amy Brooks-Kayal MD, FAAN
Description: This program will provide an overview to a general audience of neurologists and researchers on the initial navigation of novel treatments for neurological disease, going from discoveries in the lab to initial studies in human subjects. Specific examples will be used to illustrate the challenges that occur during the course of drug development. A companion session will cover the challenges beyond initial studies in healthy subjects. This program complements C148: Developing the Treatments of Tomorrow II: Clinical Trials in Neurology, but covers independent topics.
Completion Message: Participants should have an increased understanding of the steps involved in drug discovery and development up to the initial studies in healthy subjects, and will have been introduced to strategies for increasing success in later development.
CME Credits: 2
Core Competencies: Medical Knowledge, Systems-Based Practice

Program Speakers - Tentative

Start/End Time Title Faculty
1:00 PM - 1:25 PM Discovery of Novel Therapeutic Agents for CNS Disorders: Target Selection and Discovery Process Peter Lansbury PhD 
1:25 PM - 1:50 PM Entry of Novel Therapeutic Agents into Man Jang-Ho Cha MD, PhD 
1:50 PM - 2:15 PM Beyond Small Molecules: Developing Biologic Therapies Gary Starling PhD 
2:15 PM - 2:40 PM What Can Be Done to Increase Translational Success Shai Silberberg PhD 
2:40 PM - 3:00 PM Questions and Answers Faculty 

Disclosures

Speaker Disclosure
Jang-Ho John Cha, MD, PhD Dr. Cha has received personal compensation for activities with Novartis.. Dr. Cha holds stock and/or stock options in Merck and Novartis.

Peter Lansbury, PhD Dr. Lansbury has received stock and/or stock options in Orig3n.

Shai Silberberg, PhD Dr. Silberberg has nothing to disclose.

Gary Starling, PhD Dr. Starling has received personal compensation for activities with Merck & Co. as an employee. Dr. Starling hold stock and/or stock option with Merck & Co.

Register Now

Related Courses

Sunday April 22, 2018

7:00 AM-9:00 AM
C28 Faculty Development: Enhancing Your Role in Student and Resident Training Vicki Shanker MD
1:00 PM-3:00 PM
C42 Developing the Treatments of Tomorrow I: Taking Molecules from Lab to Man Amy Brooks-Kayal MD, FAAN
1:00 PM-5:30 PM
C46 Resident Basic Science II: Neuropathology Matthew Cykowski MD
3:30 PM-5:30 PM
C55 Developing the Treatments of Tomorrow II: Clinical Trials in Neurology Jeffrey Gelfand MD, MAS, FAAN

Monday April 23, 2018

1:00 PM-5:30 PM
C81 Resident Basic Science III: Neuroanatomy: All the Lesions Zachary London MD, FAAN

Tuesday April 24, 2018

1:00 PM-3:00 PM
C116 Introduction to Clinical Research and Methods Deborah Hall MD, PhD, FAAN

Wednesday April 25, 2018

1:00 PM-3:00 PM
C149 Where is the Lesion? A History of Neurological Investigations Part I Stefano Sandrone PhD
3:30 PM-5:30 PM
C164 Where is the Lesion? A History of Neurological Investigation Part II Stefano Sandrone PhD

MEMBER LOG IN

Forgot Password?